MC4R and obesity due to melanocortin 4 receptor deficiency: The α-MSH analog setmelanotide is approved for some homozygous monogenic mutations (LEPR, MC4R, POMC, PCSK1) in the leptin–melanocortin pathway to treat severe obesity and is being studied for heterozygous mutations as well [101,102].